 Kevin Messacar
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 32 | 2025 | 177 | 11.110 |
Why?
| | Myelitis | 25 | 2025 | 107 | 6.880 |
Why?
| | Enterovirus D, Human | 20 | 2025 | 85 | 6.830 |
Why?
| | Central Nervous System Viral Diseases | 17 | 2025 | 79 | 5.550 |
Why?
| | Neuromuscular Diseases | 17 | 2025 | 132 | 5.260 |
Why?
| | Enterovirus | 14 | 2025 | 86 | 4.790 |
Why?
| | Meningitis | 8 | 2022 | 79 | 3.860 |
Why?
| | Encephalitis | 12 | 2022 | 136 | 3.790 |
Why?
| | Respiratory Tract Infections | 11 | 2025 | 390 | 3.390 |
Why?
| | Disease Outbreaks | 18 | 2025 | 395 | 3.270 |
Why?
| | Parechovirus | 4 | 2025 | 8 | 2.170 |
Why?
| | Anti-Infective Agents | 5 | 2023 | 255 | 2.110 |
Why?
| | Picornaviridae Infections | 4 | 2025 | 47 | 2.020 |
Why?
| | Multiplex Polymerase Chain Reaction | 4 | 2020 | 54 | 1.810 |
Why?
| | Nervous System Diseases | 5 | 2020 | 266 | 1.740 |
Why?
| | Paralysis | 5 | 2020 | 71 | 1.630 |
Why?
| | Hospitals, Pediatric | 5 | 2020 | 508 | 1.530 |
Why?
| | Molecular Diagnostic Techniques | 6 | 2020 | 105 | 1.410 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 92 | 1.390 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 35 | 1.370 |
Why?
| | Enterovirus A, Human | 2 | 2022 | 13 | 1.350 |
Why?
| | Antimicrobial Stewardship | 4 | 2023 | 118 | 1.250 |
Why?
| | Child | 49 | 2025 | 21935 | 1.250 |
Why?
| | Communicable Diseases | 4 | 2021 | 159 | 1.180 |
Why?
| | Colorado | 21 | 2025 | 4565 | 1.170 |
Why?
| | Epidemiological Monitoring | 3 | 2021 | 60 | 1.160 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 14 | 1.090 |
Why?
| | Anti-Bacterial Agents | 6 | 2024 | 1809 | 1.020 |
Why?
| | Viruses | 4 | 2023 | 113 | 1.010 |
Why?
| | Child, Preschool | 31 | 2025 | 11074 | 0.950 |
Why?
| | Humans | 81 | 2025 | 137585 | 0.840 |
Why?
| | Simplexvirus | 2 | 2020 | 80 | 0.760 |
Why?
| | Influenza, Human | 3 | 2020 | 622 | 0.760 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 184 | 0.760 |
Why?
| | Infant | 24 | 2025 | 9465 | 0.750 |
Why?
| | Nervous System Malformations | 1 | 2022 | 42 | 0.720 |
Why?
| | Brain Diseases | 2 | 2020 | 141 | 0.720 |
Why?
| | Sepsis | 2 | 2018 | 617 | 0.700 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.700 |
Why?
| | Virus Diseases | 1 | 2022 | 212 | 0.650 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 45 | 0.640 |
Why?
| | Acyclovir | 1 | 2020 | 101 | 0.640 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 33 | 0.630 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.630 |
Why?
| | Drug Utilization | 2 | 2017 | 169 | 0.620 |
Why?
| | Hospitals, Teaching | 1 | 2019 | 118 | 0.620 |
Why?
| | Hepatitis | 1 | 2019 | 48 | 0.610 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.610 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 43 | 0.610 |
Why?
| | Neurocysticercosis | 1 | 2018 | 8 | 0.600 |
Why?
| | Meningoencephalitis | 2 | 2019 | 25 | 0.590 |
Why?
| | Abdomen | 1 | 2019 | 125 | 0.590 |
Why?
| | Gastroenteritis | 1 | 2019 | 69 | 0.590 |
Why?
| | Fluoxetine | 1 | 2018 | 54 | 0.580 |
Why?
| | Polymerase Chain Reaction | 6 | 2024 | 1062 | 0.580 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 73 | 0.570 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1483 | 0.540 |
Why?
| | Retrospective Studies | 18 | 2024 | 15657 | 0.540 |
Why?
| | Metagenomics | 6 | 2023 | 169 | 0.540 |
Why?
| | Vaccines | 1 | 2022 | 406 | 0.520 |
Why?
| | Hospitalization | 7 | 2020 | 2199 | 0.510 |
Why?
| | Seizures | 1 | 2020 | 426 | 0.510 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 20 | 0.500 |
Why?
| | Antiviral Agents | 2 | 2020 | 744 | 0.500 |
Why?
| | Bacterial Infections | 1 | 2018 | 250 | 0.500 |
Why?
| | Analgesia, Epidural | 1 | 2016 | 33 | 0.490 |
Why?
| | Fever | 2 | 2019 | 306 | 0.490 |
Why?
| | Bacteria | 3 | 2023 | 858 | 0.480 |
Why?
| | Male | 34 | 2025 | 67762 | 0.480 |
Why?
| | Microbial Sensitivity Tests | 1 | 2016 | 361 | 0.470 |
Why?
| | Health Resources | 1 | 2016 | 120 | 0.460 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.440 |
Why?
| | Motor Neurons | 1 | 2016 | 234 | 0.430 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 147 | 0.420 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2025 | 74 | 0.420 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 815 | 0.410 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 128 | 0.400 |
Why?
| | Magnetic Resonance Imaging | 5 | 2020 | 3566 | 0.390 |
Why?
| | Female | 31 | 2025 | 73304 | 0.380 |
Why?
| | United States | 15 | 2024 | 14841 | 0.380 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 394 | 0.370 |
Why?
| | Infant, Newborn | 9 | 2019 | 6079 | 0.360 |
Why?
| | Pediatrics | 1 | 2019 | 1101 | 0.360 |
Why?
| | Referral and Consultation | 1 | 2017 | 786 | 0.360 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2023 | 539 | 0.350 |
Why?
| | Quality Improvement | 1 | 2019 | 1178 | 0.350 |
Why?
| | Brain | 3 | 2018 | 2668 | 0.330 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 13 | 0.330 |
Why?
| | Seasons | 3 | 2019 | 547 | 0.330 |
Why?
| | Prospective Studies | 5 | 2025 | 7604 | 0.330 |
Why?
| | Cohort Studies | 6 | 2024 | 5742 | 0.320 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1171 | 0.310 |
Why?
| | Internship and Residency | 1 | 2019 | 1147 | 0.310 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.280 |
Why?
| | Adolescent | 17 | 2025 | 21513 | 0.260 |
Why?
| | Paramyxoviridae Infections | 1 | 2025 | 13 | 0.240 |
Why?
| | Metapneumovirus | 1 | 2025 | 16 | 0.240 |
Why?
| | Rhinovirus | 2 | 2017 | 58 | 0.230 |
Why?
| | Paraplegia | 2 | 2015 | 60 | 0.230 |
Why?
| | Sequence Analysis, DNA | 5 | 2023 | 812 | 0.220 |
Why?
| | Mycoplasma pneumoniae | 1 | 2024 | 57 | 0.220 |
Why?
| | Pleural Effusion | 1 | 2024 | 54 | 0.220 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2024 | 57 | 0.220 |
Why?
| | Acute Disease | 4 | 2019 | 1007 | 0.210 |
Why?
| | Time Factors | 4 | 2018 | 6828 | 0.200 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 17 | 0.200 |
Why?
| | Streptococcus pneumoniae | 1 | 2024 | 169 | 0.200 |
Why?
| | Canada | 3 | 2025 | 418 | 0.200 |
Why?
| | Arbovirus Infections | 2 | 2020 | 21 | 0.200 |
Why?
| | Community-Acquired Infections | 1 | 2024 | 174 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 67 | 0.190 |
Why?
| | Respiratory System | 1 | 2023 | 157 | 0.190 |
Why?
| | Pandemics | 4 | 2025 | 1639 | 0.190 |
Why?
| | Fungi | 1 | 2023 | 144 | 0.190 |
Why?
| | Uncertainty | 1 | 2022 | 128 | 0.180 |
Why?
| | Medical Oncology | 1 | 2023 | 289 | 0.180 |
Why?
| | Hashimoto Disease | 1 | 2021 | 13 | 0.180 |
Why?
| | Lung | 1 | 2014 | 4060 | 0.170 |
Why?
| | Brain Abscess | 1 | 2020 | 10 | 0.170 |
Why?
| | Esophageal Perforation | 1 | 2020 | 15 | 0.170 |
Why?
| | Esophageal Fistula | 1 | 2020 | 19 | 0.170 |
Why?
| | Antigens, Viral | 2 | 2019 | 178 | 0.170 |
Why?
| | Meningitis, Viral | 1 | 2020 | 21 | 0.170 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 21 | 0.170 |
Why?
| | Muscle Weakness | 1 | 2020 | 88 | 0.160 |
Why?
| | Confusion | 1 | 2020 | 28 | 0.160 |
Why?
| | Immunocompetence | 1 | 2019 | 42 | 0.160 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 24 | 0.160 |
Why?
| | Myelitis, Transverse | 1 | 2019 | 3 | 0.160 |
Why?
| | Seroepidemiologic Studies | 1 | 2019 | 165 | 0.150 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 34 | 0.150 |
Why?
| | HIV Infections | 1 | 2014 | 2836 | 0.150 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.150 |
Why?
| | Foreign Bodies | 1 | 2020 | 104 | 0.150 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2019 | 51 | 0.150 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 47 | 0.150 |
Why?
| | Body Fluids | 1 | 2018 | 66 | 0.140 |
Why?
| | Leukocyte Count | 1 | 2018 | 329 | 0.140 |
Why?
| | Arboviruses | 1 | 2017 | 16 | 0.140 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.140 |
Why?
| | Headache | 1 | 2018 | 147 | 0.140 |
Why?
| | Program Development | 1 | 2019 | 364 | 0.140 |
Why?
| | Refusal to Treat | 1 | 2017 | 17 | 0.130 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 110 | 0.130 |
Why?
| | Neuromyelitis Optica | 1 | 2019 | 132 | 0.130 |
Why?
| | Drug Utilization Review | 1 | 2017 | 57 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 356 | 0.130 |
Why?
| | Herpes Simplex | 1 | 2017 | 95 | 0.130 |
Why?
| | RNA | 1 | 2023 | 921 | 0.130 |
Why?
| | Movement Disorders | 1 | 2017 | 58 | 0.130 |
Why?
| | Densovirus | 1 | 2016 | 4 | 0.130 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1946 | 0.130 |
Why?
| | Prevalence | 2 | 2015 | 2734 | 0.130 |
Why?
| | Communicable Disease Control | 1 | 2017 | 82 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 114 | 0.130 |
Why?
| | Drug Resistance | 1 | 2017 | 169 | 0.130 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 17 | 0.130 |
Why?
| | Encephalomyelitis | 1 | 2016 | 12 | 0.130 |
Why?
| | Eosinophilia | 1 | 2018 | 218 | 0.130 |
Why?
| | Electromyography | 2 | 2017 | 400 | 0.130 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.120 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1236 | 0.120 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 27 | 0.120 |
Why?
| | Neoplasms | 2 | 2023 | 2671 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2016 | 242 | 0.120 |
Why?
| | North America | 1 | 2016 | 313 | 0.120 |
Why?
| | Program Evaluation | 1 | 2019 | 898 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2016 | 148 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2019 | 10811 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 871 | 0.120 |
Why?
| | La Crosse virus | 1 | 2014 | 6 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2020 | 3556 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1129 | 0.110 |
Why?
| | Encephalitis, California | 1 | 2014 | 11 | 0.110 |
Why?
| | West Nile Fever | 1 | 2014 | 54 | 0.110 |
Why?
| | Hospitals | 1 | 2019 | 691 | 0.110 |
Why?
| | Kidney | 1 | 2021 | 1468 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 167 | 0.100 |
Why?
| | Adult | 6 | 2023 | 37929 | 0.100 |
Why?
| | Neuroimaging | 1 | 2014 | 259 | 0.100 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 40 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1079 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 233 | 0.090 |
Why?
| | Critical Care | 1 | 2017 | 601 | 0.090 |
Why?
| | Clinical Competence | 1 | 2019 | 1118 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 679 | 0.090 |
Why?
| | Models, Theoretical | 2 | 2025 | 578 | 0.090 |
Why?
| | Population Surveillance | 1 | 2014 | 482 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3457 | 0.080 |
Why?
| | Risk Factors | 2 | 2020 | 10388 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5131 | 0.070 |
Why?
| | Animals | 3 | 2019 | 36940 | 0.070 |
Why?
| | Young Adult | 4 | 2019 | 13209 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1724 | 0.070 |
Why?
| | Quality of Life | 1 | 2018 | 2892 | 0.060 |
Why?
| | Models, Biological | 2 | 2025 | 1783 | 0.060 |
Why?
| | California | 2 | 2019 | 431 | 0.060 |
Why?
| | Scotland | 1 | 2025 | 18 | 0.060 |
Why?
| | Republic of Korea | 1 | 2025 | 37 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2019 | 893 | 0.060 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2024 | 48 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2016 | 499 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2691 | 0.050 |
Why?
| | Pregnancy | 1 | 2016 | 6763 | 0.050 |
Why?
| | Computational Biology | 2 | 2019 | 644 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 193 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 25 | 0.050 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 234 | 0.050 |
Why?
| | Phylogeny | 2 | 2016 | 904 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2021 | 34 | 0.040 |
Why?
| | Africa, Western | 1 | 2020 | 17 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 295 | 0.040 |
Why?
| | Technology | 1 | 2021 | 96 | 0.040 |
Why?
| | Child, Hospitalized | 1 | 2020 | 49 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 131 | 0.040 |
Why?
| | Consciousness Disorders | 1 | 2019 | 20 | 0.040 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2019 | 11 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 18 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 86 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 184 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 40 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 452 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 17 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 123 | 0.030 |
Why?
| | Guatemala | 1 | 2017 | 327 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2023 | 1069 | 0.030 |
Why?
| | Genome, Viral | 1 | 2016 | 144 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2019 | 625 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 686 | 0.030 |
Why?
| | Aftercare | 1 | 2017 | 208 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 656 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 233 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 364 | 0.030 |
Why?
| | Cost of Illness | 1 | 2016 | 308 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 94 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1215 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 402 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2804 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 1972 | 0.020 |
Why?
| | Middle Aged | 3 | 2019 | 33479 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2074 | 0.020 |
Why?
| | Autoantibodies | 1 | 2019 | 1496 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3284 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 811 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4030 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2828 | 0.020 |
Why?
| | Aged | 2 | 2019 | 23961 | 0.020 |
Why?
|
|
Messacar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|